Notice of Allowance marks first Chinese patent to be issued on Anixa Breast Cancer Vaccine Expands global intellectual property coverage in markets with high breast cancer incidence New patent will provide IP protection of Breast Cancer Vaccine in China into at least the 2040s SAN JOSE,...
Related Questions
How will the new Chinese patent approval affect Anixa Biosciences' revenue forecasts and valuation?
What competitive advantage does this IP protection give Anixa versus other breast cancer vaccine developers in China and globally?
What is the timing and likelihood of commercialization of the breast cancer vaccine in China, and how might it influence the stock's volatility?